Information Provided By: 
Fly News Breaks for July 9, 2015
CELG, EPZM
Jul 9, 2015 | 10:20 EDT
Mizuho analyst Peter Lawson views Epizyme (EPZM) as a "cleaner" acquisition target following its revised agreement with Celgene (CELG). Celgene will no longer have right of first negotiation regarding acquisitions, Lawson tells investors in a research note. He views the new and extended agreement as a net positive for Epizyme, but admits it’s hard to compare to the prior one. He keeps a Buy rating on the stock with a $29 price target.
News For EPZM;CELG From the Last 2 Days
There are no results for your query EPZM;CELG
